Dr Kathryn Higgins

Kate has a background in Pharmacology and a PhD in the inflammatory system. She began her employment at TGI in March 2018, mainly working within the renal and metabolic division. Kate’s clinical research operations skills developed whilst working on the REDUCCTION study where she managed sites, coordinated event adjudication processes, maintained data trackers, monitored data collection, upheld ethics and research governance approvals, submitted ethics amendments, coordinated site payments, and maintained close communication with participating study sites. Her expertise has also been lent to other studies including TRIDENT (project forecasting and coordinating outcome adjudications), TRACK (unblinded team member), RESOLVE (event verification), and ATHENA (UAT). Experience has also been obtained in start-up, site initiation, site close-out, protocol and other document development, and exposure to data linkage processes.

Kate currently manages the PERFORM-AKI, ACCESS HD, DISCOVER and REVERSE studies.